2
Participants
Start Date
July 31, 2025
Primary Completion Date
July 31, 2026
Study Completion Date
July 31, 2026
NF54/iGP3
Mosquito-generated sporozoites of the genetically modified, inducible gametocyte-producing parasite line NF54/iGP3, created via CRISPR/Cas9 genetic engineering of the parental wildtype strain Plasmodium falciparum (Pf) NF54 to contain a trimethoprim (TMP)-inducible copy of the Pf gdv1 gene in the dispensable Pf cg6 locus.
Doherty Clinical Trials, Melbourne
Walter and Eliza Hall Institute of Medical Research
OTHER
Swiss Tropical & Public Health Institute
OTHER
QIMR Berghofer Medical Research Institute
OTHER
University of Melbourne
OTHER